To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity

Registration

Registration

NCT03795701

Study type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

QUADRUPLE

Status

COMPLETED

Enrollment

73

Start

2019-01-08

Primary completion

2022-05-01

Lead sponsor

Texas Tech University

Conditions

Obesity

Interventions

DRUG:Saxenda®; OTHER:Placebo

Results posted

FALSE

Registered primary outcomes

• Compare the changes of pre-prandial fMRI-FCR in Liraglutide 3.0 vs. Placebo Group [Baseline, Week 4, and Week 16]
• Compare the changes of post-prandial fMRI-FCR in Liraglutide 3.0 vs. Placebo Group [Baseline, Week 4, and Week 16]
• Compare the changes of energy intake in Liraglutide 3.0 vs. Placebo Group [Baseline, Week 4, and Week 16]
• Compare the changes of hunger/satiety in Liraglutide 3.0 vs. Placebo Group [Baseline, Week 4, and Week 16]
• Prediction of weight loss in Liraglutide 3.0 group by examine early change in pre-prandial fMRI-FCR [Baseline, Week 4, and Week 16]
• Prediction of weight loss in Liraglutide 3.0 group by examine early change in post-prandial fMRI-FCR [Baseline, Week 4, and Week 16]